期刊文献+

浅谈肿瘤体外诊断试剂的临床试验设计 被引量:1

Clinical scheme design of in vitro tumor diagnostic reagents
原文传递
导出
摘要 肿瘤是严重威胁人类健康的高发病率和高死亡率疾病,肿瘤体外诊断试剂的普及运用提高了肿瘤的诊疗水平。为了充分发挥肿瘤体外诊断试剂在临床使用中的价值,本文将结合《体外诊断试剂质量管理体系考核实施规定(试行)》、《体外诊断试剂临床研究技术指导原则》、《体外诊断试剂注册管理办法(试行)》等法律法规的要求及国内外肿瘤诊断试剂研究进展,浅谈肿瘤体外诊断试剂临床验证的试验设计。(中华检验医学杂志,2014,37:645-648) Cancer is a serious threat to human health with high morbidity and high mortality , using vitro tumor diagnostic reagents can improve the level of diagnosis and treatment.In order to develop the value of in vitro tumor diagnostic reagents in clinical use , this article would analyze “in vitro diagnostic reagents technical guidelines for clinical research” ,“in vitro diagnostic reagents registration” and other laws and regulations ,as well as the development of research in domestic and foreign.To discuss the clinical scheme design and development trend of in vitro tumor diagnostic reagents.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2014年第9期645-648,共4页 Chinese Journal of Laboratory Medicine
基金 国家高技术研究发展计划(863计划)资助项目(2011AA02A110) 国家重大新药创制科技重大专项资助项目(2012ZX09303012-001) 北京市科技计划重大项目(D141100000214005)
关键词 肿瘤 试剂盒 诊断 体外研究 研究设计 Neoplasms Reagent kits,diagnostic in vitro Research design
  • 相关文献

参考文献5

二级参考文献28

  • 1张文,周强,黄宪章.临床检验抗凝剂特点及应用[J].广东医学,2005,26(8):1158-1160. 被引量:17
  • 2Farzadnia M,Meibodi NT,Shandiz FH,et al.Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer:correlation with clinicopathological parameters.Breast,2010,19:489-492.
  • 3Walker RA,Bartlett JM,Dowsett M,et al.HER2 testing in the UK:further update to recommendations.J Clin Pathol,2008,61:818-824.
  • 4Marchio C,Lambros MB,Gugliotta P,et al.Does chromosome 17centromere copy number predict polysomy in breast cancer? A fiuorescence in situ hybridization and microarray-based CGH analysis.J Pathol,2009,219:16-24.
  • 5Slamon DJ,Clark GM,Wong SG,et al.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science,1987,235:177-182.
  • 6Smith I,Procter M,Gelber RD,et al.2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer:A randomized controlled trial.Lancet,2007,369:29-36.
  • 7Piccart M,Lohrisch C,Di Leo k,et al.The predictive value of HER2 in breast cancer.Oncology,2001,61suppl 2:73-82.
  • 8Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2testing in breast cancer.J Clin Oncol,2007,25:118-145.
  • 9Mass RD,Press MF,Anderson S,et al.Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.Clin Breast Cancer,2005,6:240-246.
  • 10Vanden Bempt I,Van Loo P,Drijkoningen M,et al.Polysomy 17in breast cancer:clinicopathologic significance and impact on HER-2 testing.J Clin Oncol,2008,26:4869-4874.

共引文献135

同被引文献2

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部